Regulation of apoprotein synthesis and secretion in the human hepatoma Hep G2. The effect of exogenous lipoprotein.
The regulation of lipoprotein assembly and secretion at a molecular level is incompletely understood. To begin to identify the determinants of apoprotein synthesis and distribution among lipoprotein classes, we have examined the effects of chylomicron remnants which deliver triglyceride and cholesterol, and beta very low density lipoprotein (beta VLDL), which deliver primarily cholesterol, on apolipoprotein synthesis and secretion by the human hepatoma Hep G2. Hep G2 cells were incubated with remnants or beta VLDL for 24 h, the medium was changed and the cells then incubated with [35S]methionine. The secreted lipoproteins were separated by gradient ultracentrifugation and the radiolabeled apoproteins were isolated by immunoprecipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis and counted. Remnants caused a 14-fold, and beta VLDL a 7-fold, increase in VLDL apoprotein (apo) secretion; the apoB/apoE ratio in this class was unchanged. Preincubation with either of the lipoproteins also stimulated low density lipoprotein apoB secretion. Preincubation with beta VLDL, but not with remnants, significantly increased apoE and apoA-I secreted in high density lipoprotein (HDL). In addition, the apoE/apoA-I ratio precipitated from the HDL of beta VLDL-treated cells by anti-apoE was 2.2-fold higher than that precipitated by anti-apoA-I. There was no difference in the ratios precipitated from control HDL. This was due to the secretion of a lipoprotein, subsequently isolated by immunoaffinity chromatography, that contained predominantly apoE. When Hep G2 cells were preincubated with oleic acid alone, total apoprotein secretion was not altered. However, cholesterol-rich liposomes stimulated secretion of newly synthesized apoE, but not apoB, while apoA-I secretion was variably affected. Cholesterol-poor liposomes had no effect. Thus, lipid supply is a determinant of apoprotein synthesis and secretion, and cholesterol may be of particular importance in initiating apoprotein synthesis.
Craig
W Y
WY
Department of Medicine, Stanford University, California 94305.
Nutik
R
R
Cooper
A D
AD
D016632:Apolipoprotein A-I; D001054:Apolipoproteins A / Q000096:biosynthesis / Q000378:metabolism; D001055:Apolipoproteins B / Q000096:biosynthesis / Q000378:metabolism; D001057:Apolipoproteins E / Q000096:biosynthesis / Q000378:metabolism; D001059:Apoproteins / Q000096:biosynthesis / Q000378:metabolism*; D006528:Carcinoma, Hepatocellular / Q000378:metabolism*; D002499:Centrifugation, Density Gradient; D002784:Cholesterol / Q000494:pharmacology; D002914:Chylomicrons / Q000494:pharmacology; D004591:Electrophoresis, Polyacrylamide Gel; D005230:Fatty Acids, Nonesterified / Q000494:pharmacology; D007163:Immunosorbent Techniques; D008074:Lipoproteins / Q000378:metabolism / Q000494:pharmacology*; D008077:Lipoproteins, LDL / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000494:pharmacology; D008081:Liposomes; D008113:Liver Neoplasms / Q000378:metabolism*; D008715:Methionine / Q000378:metabolism; D014280:Triglycerides / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D016632:Apolipoprotein A-I; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D001057:Apolipoproteins E; D001059:Apoproteins; D002914:Chylomicrons; D005230:Fatty Acids, Nonesterified; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D008081:Liposomes; D014280:Triglycerides; D002784:Cholesterol; D008715:Methionine